Glutaric Acid
CAS NO. :110-94-1
Synonyms: •1,3-Propanedicarboxylic acid •1,5-Pentanedioic acid •n-Pyrotartaric acid •Pentandioic acid •Pentanedioic acid
Chemicl Formula: CH3OOC-(CH2)3-COOCH3
Formula weight: |
132.116 g/mole |
R(F): |
0.0415 |
a: |
12.968 Å |
b: |
4.830 Å |
c: |
9.982 Å |
α (alpha): |
90.00 ° |
β (beta): |
96.87 ° |
γ (gamma): |
90.00 ° |
Volume: |
620.68 Å3 |
Space group: |
C2/c |
Physical Properties:
Relative density (water = 1): 1.424 (25 ℃), 1.429 (15 ℃)
Vapor Pressure: 0.000223mmHg at 25 ° C
Refractive index: 1.418 78 (106 ℃)
Solubility: soluble in water, ethanol, ether and chloroform, slightly soluble in petroleum ether.
Brief Introductions:
Glutaric acid is a colorless liquid and white crystals as a solid occurring in plants and animal tissues.
It is used in organic synthesis and as an intermediate for the manufacture of polymers
such as polyamides and polyesters, ester plasticizers and corrosion inhibitors.
It is also useful in the application of decreasing polymer elasticity and in a variety of industrial applications.
In addition glutaric acid plays an important role as an intermediary in the Krebs cycle and is used in medication
against a large number of viruses and in animal diabetes. Glutaric acid can be prepared from cyclopentanone
by oxidative ring fission with nitric acid and in the presence of a catalyst.
Glutaric acid has the lowest melting point among dicarboxylic acids (98 C);
it is very soluble in water and the solution in water is a medium strong acid.
Specifications:
Assay, % |
≥99.0 |
Melt point, ℃ |
95~98 |
Moisture, % |
≤0.15 |
Residue after ignition, % |
≤0.10 |
Succinic acid+Adipic Acid % |
≤0.5 |
VOC |
≦1% |
Appearance of solution |
Clear |
Applications:
Glutaric acid is used as food additive ,solder flux and special monomers e.g low viscosity polyester, weather resistant polymer etc.
Packing: 25kg/paper drum
Typical Data in CoA :
Quality Assurance Data |
Test Value |
Assay, % |
99.38 |
Melt point, ℃ |
97.2 |
Moisture, % |
0.14 |
Residue after ignition, % |
0.03 |
Succinic acid+Adipic Acid % |
0.29 |
VOC |
0.11 |
Appearance of solution |
Pass |
Glutaric Acid is recovered from by-products of adipic acid in the industry.
1. Preparation of the γ- butyrolactone glutaric acid γ- butyrolactone and potassium cyanide was heated
to 190-195 ℃, the reaction was stirred 2h. Cooled, concentrated hydrochloric acid amide generate glutaryl,
plus hot water solution that was ketoglutarate. Yield of 71-75%.
2. dihydropyran prepared from glutaric acid dihydropyran with 0.2N nitric acid was heated on a boiling water
bath for dissolution, and then cooled in an ice water bath, was added concentrated nitric acid, nitrogen dioxide
dihydropyran hydrolyzed and escape, when the temperature was lowered to 0 ℃, sodium nitrate was added, with
vigorous stirring 3h. Longer cooling, the temperature was raised to 25-30 ℃. Evaporated under reduced pressure,
cooled to give glutaric acid, yield 70-75%.
3. Preparation by glutaronitrile glutaronitrile glutaric acid and hydrochloric acid was heated to reflux for 4h,
then evaporated to dryness, the residue containing a glutaric acid and ammonium chloride, extracted with hot ether,
diethyl ether extract was recovered to obtain glutaric acid , available recrystallized from chloroform or benzene.
4. When cyclohexanone oxidation of cyclohexanone by nitric oxide production of adipic acid, glutaric byproduct.
5. Recovery Act paraffin oxidation byproduct recovery ketoglutarate production oxidized paraffin.
Recovery method commonly used water extraction method (or distillation, flash and steam distillation, etc.)
and crystallization.
6. cyclopentanone phase oxidation.
7. dihydrofuran method. Laboratory also used for preparing 1,3-propanediol glutaric acid
Glutaric acid
CAS Number 110-94-1
Chemical Name Pentanedioic acid
Type of substance Organic
SMILES O=C(O)CCCC(=O)O
Moiety of concern organic
Classification
6.4A Irritating to the eye
Classification Data
6.4A R PHRASE: R 36
TYPES OF
HAZARD /
EXPOSURE ACUTE HAZARDS / SYMPTOMS PREVENTION FIRST AID / FIRE FIGHTING
FIRE Combustible. NO open flames. Use water spray, powder.
EXPLOSION
EXPOSURE
Inhalation Cough. Sore throat. Use local exhaust or breathing protection. Fresh air, rest.
Skin Redness. Pain. Protective gloves. Remove contaminated clothes. Rinse skin with plenty of water or shower.
Eyes Pain. Redness. Wear safety spectacles or safety goggles. First rinse with plenty of water for several minutes (remove contact lenses if easily possible), then refer for medical attention.
Ingestion Abdominal pain. Do not eat, drink, or smoke during work. Rinse mouth. Give one or two glasses of water to drink. Refer for medical attention .
SPILLAGE DISPOSAL
PACKAGING & LABELLING
Sweep spilled substance into covered containers. If appropriate, moisten first to prevent dusting. Then wash away with plenty of water.
EC Classification
UN Classification
GHS Classification
EMERGENCY RESPONSE SAFE STORAGE
Separated from bases.
IMPORTANT DATA
Physical State; Appearance
COLOURLESS CRYSTALS.
Physical dangers
Chemical dangers
The solution in water is a medium strong acid.
Occupational exposure limits
TLV (NOT-ESTABLISHED):.
Routes of exposure
The substance can be absorbed into the body by inhalation of its aerosol.
Inhalation risk
Evaporation at 20°C is negligible; a harmful concentration of airborne particles can, however, be reached quickly when dispersed.
Effects of short-term exposure
The substance is irritating to the eyes, skin and respiratory tract.
Effects of long-term or repeated exposure
PHYSICAL PROPERTIES ENVIRONMENTAL DATA
Decomposes at 302-304°C
Melting point: 98°C
Density: 1.4 g/cm3
Solubility in water, g/100ml at 20°C: 63.9
Octanol/water partition coefficient as log Pow: -0.47/-0.08 (calculated)
inherent toxicity to aquatic organisms (Show Details...)
Pivotal value for iT (mg/l) 223.1
Toxicity to fathead minnow (LC50 in mg/l) as predicted by Topkat v6.1 223.1
Toxicity to fish (LC50 in mg/l) as predicted by Ecosar v0.99g 130,000
Toxicity to fish (LC50 in mg/l) as predicted by Oasis Forecast M v1.10 57,389.6406
Toxicity to fish (LC50 in mg/l) as predicted by Aster 24,591.426
Toxicity to fish (LC50 in mg/l) as predicted by PNN 10,067.40373
Toxicity to daphnia (EC50 in mg/l) as predicted by Topkat v6.1 0.2006
Toxicity to fish, daphnia, algae or mysid shrimp (EC50 or LC50 in mg/l) as predicted by Ecosar v0.99g 16,497.533
Chronic toxicity to daphnia or algae (EC50 in mg/l) as predicted by Ecosar v0.99g 2,281.177
Toxicity to fish (LC50 in mg/l) as predicted by Neutral Organics QSAR in Ecosar v0.99g 1.30E+002
Bioaccumulation (Hide Details...)
Empirical Log Kow -0.29
Log Kow predicted by KowWin -0.26
Log BAF T2MTL predicted by Gobas 0.0000540371955876
Log BCF 5% T2LTL predicted by Gobas 0.0005144646215092
Log BCF Max predicted by OASIS 1.02344193516906
Log BCF predicted by BCFWIN 0.5
Emergency Medical Treatment:
EMT Copyright Disclaimer:
The information contained in the Truven Health Analytics Inc. products is intended as an educational aid only. All treatments or procedures are intended to serve as an information resource for physicians or other competent healthcare professionals performing the consultation or evaluation of patients and must be interpreted in view of all attendant circumstances, indications and contraindications. The use of the Truven Health Analytics Inc. products is at your sole risk. These products are provided "as is" and "as available" for use, without warranties of any kind, either express or implied. Truven Health Analytics Inc. makes no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the productsAdditionally, Truven Health ANALYTICS INC. makes no representation or warranties as to the opinions or other service or data you may access, download or use as a result of use of the Truven Health ANALYTICS INC. products. All implied warranties of merchantability and fitness for a particular purpose or use are hereby excluded. Truven Health Analytics Inc. does not assume any responsibility or risk for your use of the Truven Health Analytics Inc. products.
The following Overview, *** GENERAL OR UNKNOWN CHEMICAL ***, is relevant for this HSDB record chemical.
Life Support:
o This overview assumes that basic life support measures
have been instituted.
Clinical Effects:
0.2.1 SUMMARY OF EXPOSURE
0.2.1.1 ACUTE EXPOSURE
A) A SPECIFIC REVIEW on the clinical effects and treatment
of individuals exposed to this agent HAS NOT YET BEEN
PREPARED. The following pertains to the GENERAL
EVALUATION and TREATMENT of individuals exposed to
potentially toxic chemicals.
B) GENERAL EVALUATION -
1) Exposed individuals should have a careful, thorough
medical history and physical examination performed,
looking for any abnormalities. Exposure to chemicals
with a strong odor often results in such nonspecific
symptoms as headache, dizziness, weakness, and nausea.
C) IRRITATION -
1) Many chemicals cause irritation of the eyes, skin, and
respiratory tract. In severe cases respiratory tract
irritation can progress to ARDS/acute lung injury,
which may be delayed in onset for up to 24 to 72 hours
in some cases.
2) Irritation or burns of the esophagus or
gastrointestinal tract are also possible if caustic or
irritant chemicals are ingested.
D) HYPERSENSITIVITY -
1) A number of chemical agents produce an allergic
hypersensitivity dermatitis or asthma with
bronchospasm and wheezing with chronic exposure.
Laboratory:
A) A number of chemicals produce abnormalities of the
hematopoietic system, liver, and kidneys. Monitoring
complete blood count, urinalysis, and liver and kidney
function tests is suggested for patients with significant
exposure.
B) If respiratory tract irritation or respiratory depression
is evident, monitor arterial blood gases, chest x-ray,
and pulmonary function tests.
Treatment Overview:
0.4.2 ORAL EXPOSURE
A) GASTRIC LAVAGE
1) Significant esophageal or gastrointestinal tract
irritation or burns may occur following ingestion. The
possible benefit of early removal of some ingested
material by cautious gastric lavage must be weighed
against potential complications of bleeding or
perforation.
2) GASTRIC LAVAGE: Consider after ingestion of a
potentially life-threatening amount of poison if it can
be performed soon after ingestion (generally within 1
hour). Protect airway by placement in the head down
left lateral decubitus position or by endotracheal
intubation. Control any seizures first.
a) CONTRAINDICATIONS: Loss of airway protective reflexes
or decreased level of consciousness in unintubated
patients; following ingestion of corrosives;
hydrocarbons (high aspiration potential); patients at
risk of hemorrhage or gastrointestinal perforation;
and trivial or non-toxic ingestion.
B) ACTIVATED CHARCOAL
1) Activated charcoal binds most toxic agents and can
decrease their systemic absorption if administered soon
after ingestion. In general, metals and acids are
poorly bound and patients ingesting these materials
will not likely benefit from activated charcoal
administration.
a) Activated charcoal should not be given to patients
ingesting strong acidic or basic caustic chemicals.
Activated charcoal is also of unproven value in
patients ingesting irritant chemicals, where it may
obscure endoscopic findings when the procedure is
justified.
2) ACTIVATED CHARCOAL: Administer charcoal as a slurry
(240 mL water/30 g charcoal). Usual dose: 25 to 100 g
in adults/adolescents, 25 to 50 g in children (1 to 12
years), and 1 g/kg in infants less than 1 year old.
C) DILUTION -
1) Immediate dilution with milk or water may be of benefit
in caustic or irritant chemical ingestions.
2) DILUTION: If no respiratory compromise is present,
administer milk or water as soon as possible ingestion.
Dilution may only be helpful if performed in the first
seconds to minutes after ingestion. The ideal amount is
unknown; no more than 8 ounces (240 mL) in adults and 4
ounces (120 mL) in children is recommended to minimize
the risk of vomiting.
D) IRRITATION -
1) Observe patients with ingestion carefully for the
possible development of esophageal or gastrointestinal
tract irritation or burns. If signs or symptoms of
esophageal irritation or burns are present, consider
endoscopy to determine the extent of injury.
E) OBSERVATION CRITERIA -
1) Carefully observe patients with ingestion exposure for
the development of any systemic signs or symptoms and
administer symptomatic treatment as necessary.
2) Patients symptomatic following exposure should be
observed in a controlled setting until all signs and
symptoms have fully resolved.
0.4.3 INHALATION EXPOSURE
A) DECONTAMINATION -
1) INHALATION: Move patient to fresh air. Monitor for
respiratory distress. If cough or difficulty breathing
develops, evaluate for respiratory tract irritation,
bronchitis, or pneumonitis. Administer oxygen and
assist ventilation as required. Treat bronchospasm with
an inhaled beta2-adrenergic agonist. Consider systemic
corticosteroids in patients with significant
bronchospasm.
B) IRRITATION -
1) Respiratory tract irritation, if severe, can progress
to pulmonary edema which may be delayed in onset up to
24 to 72 hours after exposure in some cases.
C) ACUTE LUNG INJURY -
1) ACUTE LUNG INJURY: Maintain ventilation and oxygenation
and evaluate with frequent arterial blood gases and/or
pulse oximetry monitoring. Early use of PEEP and
mechanical ventilation may be needed.
D) BRONCHOSPASM -
1) If bronchospasm and wheezing occur, consider treatment
with inhaled sympathomimetic agents.
E) OBSERVATION CRITERIA -
1) Carefully observe patients with inhalation exposure for
the development of any systemic signs or symptoms and
administer symptomatic treatment as necessary.
2) Patients symptomatic following exposure should be
observed in a controlled setting until all signs and
symptoms have fully resolved.
0.4.4 EYE EXPOSURE
A) DECONTAMINATION: Remove contact lenses and irrigate
exposed eyes with copious amounts of room temperature
0.9% saline or water for at least 15 minutes. If
irritation, pain, swelling, lacrimation, or photophobia
persist after 15 minutes of irrigation, the patient
should be seen in a healthcare facility.
0.4.5 DERMAL EXPOSURE
A) OVERVIEW
1) DERMAL DECONTAMINATION -
a) DECONTAMINATION: Remove contaminated clothing and
jewelry and place them in plastic bags. Wash exposed
areas with soap and water for 10 to 15 minutes with
gentle sponging to avoid skin breakdown. A physician
may need to examine the area if irritation or pain
persists (Burgess et al, 1999).
2) PESTICIDES -
a) DECONTAMINATION: Remove contaminated clothing and
jewelry and place them in plastic bags. Wash exposed
areas with soap and water for 10 to 15 minutes with
gentle sponging to avoid skin breakdown. A physician
may need to examine the area if irritation or pain
persists (Burgess et al, 1999).
3) IRRITATION -
a) Treat dermal irritation or burns with standard topical
therapy. Patients developing dermal hypersensitivity
reactions may require treatment with systemic or
topical corticosteroids or antihistamines.
4) DERMAL ABSORPTION -
a) Some chemicals can produce systemic poisoning by
absorption through intact skin. Carefully observe
patients with dermal exposure for the development of
any systemic signs or symptoms and administer
symptomatic treatment as necessary.
Range of Toxicity:
A) No specific range of toxicity can be established for the
broad field of chemicals in general.
[Rumack BH POISINDEX(R) Information System Micromedex, Inc., Englewood, CO, 2015; CCIS Volume 164, edition expires May, 2015. Hall AH & Rumack BH (Eds): TOMES(R) Information System Micromedex, Inc., Englewood, CO, 2015; CCIS Volume 164, edition expires May, 2015.] **PEER REVIEWED**
Metabolism/ Pharmacokinetics:
Metabolism/ Metabolites:
RAT LIVER MITOCHONDRIA METABOLIZED GLUTARATE VERY SLOWLY COMPARED WITH GLUTARYL-COENZYME A (COA). GLUTARYL-COA DEHYDROGENASE, WHICH CATALYZES THE STOICHIOMETRIC CONVERSION OF GLUTARYL-COA TO 1 MOLE EACH OF CARBON DIOXIDE AND CROTONYL-COA OR ITS INTERMEDIATE METABOLITE, WAS PURIFIED APPROX 44- AND 100-FOLD FROM BOVINE LIVER AND KIDNEY MITOCHONDRIA, RESPECTIVELY. THE KM FOR GLUTARYL-COA WAS 3.3 MUM.
[BESRAT A ET AL; MAMMALIAN METABOLISM OF GLUTARIC ACID; J BIOL CHEM 244(6) 1461 (1969)] **PEER REVIEWED**
Interactions:
LITHIUM CHLORIDE (1.15 G) OR LITHIUM CARBAMATE (1.5-4 G) INCREASED THE RENAL EXCRETION OF GLUTARATE IN MANIC DEPRESSIVE PATIENTS. THE EFFECTS OF LITHIUM ARE PROBABLY CAUSED BY DECREASED RENAL TUBULAR RESORPTION.
[BOND PA ET AL; EFFECT OF LITHIUM SALTS ON THE URINARY EXCRETION OF ALPHA- OXOGLUTARATE IN MAN; BRIT J PHARMACOL 46(1) 116 (1972)] **PEER REVIEWED**
Pharmacology:
Therapeutic Uses:
EXPTL USE: GLUTARIC ACID HAD IN VITRO VIRUCIDAL ACTIVITY AGAINST LARGE NUMBER OF VIRUSES SUCH AS RHINOVIRUS & HERPES.
[GUY DD; COMPOSITION CONTAINING GLUTARIC ACID AS A VIRUCIDAL AGENT; EUR PAT APPL PATENT NUMBER 8121 02/20/80 (STERLING DRUG IND)] **PEER REVIEWED**
MEDICATION (VET): GLUTARIC ACID & P-AMINOBENZOIC ACID BLOCKED NET FLUID SECRETION CAUSED BY CHOLERA TOXIN OR THE HEAT-STABLE ENTEROTOXIN OF ESCHERICHIA COLI. THE TISSUE EXAMINED WAS LIGATED JEJUNAL LOOPS IN WEANLING PIGS.
[FORSYTH GW ET AL; ORGANIC ACID PROTON DONORS DECREASE INTESTINAL SECRETION CAUSED BY ENTEROTOXINS; AM J PHYSIOL 241(3) G227 (1981)] **QC REVIEWED**
AGENT IN ANIMAL DIABETES & BIOCHEMICAL RESEARCH
[SRI] **QC REVIEWED**
Interactions:
LITHIUM CHLORIDE (1.15 G) OR LITHIUM CARBAMATE (1.5-4 G) INCREASED THE RENAL EXCRETION OF GLUTARATE IN MANIC DEPRESSIVE PATIENTS. THE EFFECTS OF LITHIUM ARE PROBABLY CAUSED BY DECREASED RENAL TUBULAR RESORPTION.
[BOND PA ET AL; EFFECT OF LITHIUM SALTS ON THE URINARY EXCRETION OF ALPHA- OXOGLUTARATE IN MAN; BRIT J PHARMACOL 46(1) 116 (1972)] **PEER REVIEWED**
Environmental Fate & Exposure:
Natural Pollution Sources:
OCCURS IN GREEN SUGAR BEETS; IS FOUND IN WATER EXTRACTS OF CRUDE WOOL.
[The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 579] **PEER REVIEWED**
Chemical/Physical Properties:
Molecular Formula:
C5-H8-O4
**PEER REVIEWED**
Molecular Weight:
132.13
**PEER REVIEWED**
Color/Form:
LARGE, MONOCLINIC PRISMS
[The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 579] **PEER REVIEWED**
COLORLESS CRYSTALS
[Hawley, G.G. The Condensed Chemical Dictionary. 9th ed. New York: Van Nostrand Reinhold Co., 1977., p. 416] **PEER REVIEWED**
Boiling Point:
200 DEG C @ 20 MM HG
[The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 579] **PEER REVIEWED**
Melting Point:
97.5-98 DEG C
[The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 579] **PEER REVIEWED**
Density/Specific Gravity:
1.429 @ 15 DEG C/4 DEG C
[The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 579] **PEER REVIEWED**
Dissociation Constants:
K1 @ 25 DEG: 4.60X10-5; K2: 6.0X10-6
[The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 579] **PEER REVIEWED**
Solubilities:
SOLUBILITY IN WATER (G/L): @ 0 DEG: 429; @ 20 DEG: 639; @ 50 DEG: 957; @ 65 DEG: 1118; FREELY SOL IN ABSOLUTE ALCOHOL, ETHER; SOL IN BENZENE, CHLOROFORM; SLIGHTLY SOL IN PETROLEUM ETHER
[The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 579] **PEER REVIEWED**
SOL IN CONCENTRATED SULFURIC ACID
[Weast, R.C. (ed.). Handbook of Chemistry and Physics. 60th ed. Boca Raton, Florida: CRC Press Inc., 1979., p. C-415] **PEER REVIEWED**
Spectral Properties:
INDEX OF REFRACTION: 1.41878 @ 106 DEG C/D
[The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 579] **PEER REVIEWED**
IR: 7386 (Sadtler Research Laboratories Prism Collection)
[Weast, R.C. and M.J. Astle. CRC Handbook of Data on Organic Compounds. Volumes I and II. Boca Raton, FL: CRC Press Inc. 1985., p. V1 663] **QC REVIEWED**
NMR: 4409 (Sadtler Research Laboratories Prism Collection)
[Weast, R.C. and M.J. Astle. CRC Handbook of Data on Organic Compounds. Volumes I and II. Boca Raton, FL: CRC Press Inc. 1985., p. V1 663] **QC REVIEWED**
NMR: 4409 (Sadtler Research Laboratories Spectral Collection)
[Weast, R.C. and M.J. Astle. CRC Handbook of Data on Organic Compounds. Volumes I and II. Boca Raton, FL: CRC Press Inc. 1985., p. V2 18] **QC REVIEWED**
MASS: 77 (Aldermaston, Eight Peak Index of Mass Spectra, UK)
[Weast, R.C. and M.J. Astle. CRC Handbook of Data on Organic Compounds. Volumes I and II. Boca Raton, FL: CRC Press Inc. 1985., p. V1 663] **QC REVIEWED**
Other Chemical/Physical Properties:
VERY SLIGHT DECOMPOSITION AT 302-304 DEG C
[The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 579] **PEER REVIEWED**
Manufacturing/Use Information:
Uses:
IN ORGANIC SYNTHESIS
[Hawley, G.G. The Condensed Chemical Dictionary. 9th ed. New York: Van Nostrand Reinhold Co., 1977., p. 416] **PEER REVIEWED**
CHEM INT FOR POLYMERS, EG, POLYAMIDES & POLYESTERS
[SRI] **PEER REVIEWED**
CHEM INT FOR ITS ESTERS & ANHYDRIDE
[SRI] **PEER REVIEWED**
MEDICATION (See also: Therapeutic Uses)
**QC REVIEWED**
MEDICATION (VET) (See also: Therapeutic Uses)
**QC REVIEWED**
Manufacturers:
E I du Pont de Nemours & Co, Inc, Hq, 1007 Market Street, Wilmington, DE 19898, (302) 774-1000; Petrochemicals Department; Production site: Orange, TX 77630
[SRI. 1989 Directory of Chemical Producers -United States of America. Menlo Park, CA: SRI International, 1989., p. 675] **UNREVIEWED**
United-Guardian, Inc, PO Box 2500, Smithtown, NY 11787, (516) 273-0900; Guardian Chemical Division; Eastern Chemical Division, Department St, PO Box 2500, Smithtown, NY 11787; Production site: Hauppauge, NY 11787
[SRI. 1989 Directory of Chemical Producers -United States of America. Menlo Park, CA: SRI International, 1989., p. 675] **UNREVIEWED**
Methods of Manufacturing:
MANUFACTURED FROM CYCLOPENTANONE BY OXIDATIVE RING FISSION WITH HOT 50% NITRIC ACID IN THE PRESENCE OF VANADIUM CYANIDE. LAB PREPN BY ACID HYDROLYSIS OF TRIMETHYLENE CYANIDE...OR OF METHYLENEDIMALONIC ESTER.
[The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 579] **PEER REVIEWED**
OXIDATION OF CYCLOPENTANONE WITH 50% NITRIC ACID IN THE PRESENCE OF VANADIUM PENTOXIDE OR WITH AIR IN THE PRESENCE OF A CATALYST; BY-PRODUCT IN THE PRODUCTION OF ADIPIC ACID FROM CYCLOHEXANE BY OXIDATION WITH AIR & NITRIC ACID
[SRI] **PEER REVIEWED**
General Manufacturing Information:
15,000 CU M/HR OFFGAS CONTAINING 10-15% SULFUR DIOXIDE & 0.5-2 MG H2S/CU M IS SCRUBBED IN 4 SUCCESSIVE PACKED COLUMNS @ 35 DEG C WITH 40-55 CU M/HR 30% AQ GLUTARIC ACID.
[LOWICKI N ET AL; IMPROVED METHODS FOR REMOVAL OF SULFUR DIOXIDE FROM GAS STREAMS; GER OFFEN PATENT NUMBER 2905957 12/20/79 (GRILLO-WERKE A-G)] **PEER REVIEWED**
A COMPOSITION FOR NEUTRALIZING OR DESTROYING A SUSCEPTIBLE VIRUS ON INFECTED TISSUE OF A LIVING MAMMAL CONTAINS AN EFFECTIVE CONCN OF GLUTARIC ACID IN PHARMACEUTICAL VEHICLE AS WELL AS PAPER OR CLOTH COATED OR IMPREGNATED WITH THE VIRUCIDE.
[DIANA GD; VIRUCIDAL GLUTARIC ACID FORMULATION FOR THERAPEUTIC USE EUR PAT APPL PATENT NUMBER 49354 04/14/82 (STERLING DRUG INC)] **PEER REVIEWED**
GLUTARIC ACID MAY BE AN ESSENTIAL PRECURSOR IN THE BIOSYNTHESIS OF BIOTIN BY A SPECIES OF AGROBACTERIUM.
[OGATA K ET AL; GLUTARIC ACID, A NEW PRECURSOR OF BIOTIN BIOSYNTHESIS; AGR BIOL CHEM 34(12) 1870 (1970)] **PEER REVIEWED**
U. S. Production:
(1977) AT LEAST 4.54X10+9 GRAMS
[SRI] **PEER REVIEWED**
(1981) No Data
[SRI] **PEER REVIEWED**
U. S. Imports:
(1979) No Data
[SRI] **PEER REVIEWED**
(1981) No Data
[SRI] **PEER REVIEWED**
U. S. Exports:
(1979) No Data
[SRI] **PEER REVIEWED**
(1981) No Data
[SRI] **PEER REVIEWED**
Laboratory Methods:
Analytic Laboratory Methods:
AEROSOL PARTICLE ANALYSIS WAS DETERMINED ON GLUTARIC ACID BY MEANS OF MASS SPECTROSCOPY.
[SINHA MP ET AL; PARTICLE ANALYSIS BY MASS SPECTROMETRY; J COLLOID INTERFACE SCI 87(1) 140 (1982)] **PEER REVIEWED**
Synonyms and Identifiers:
Synonyms:
PENTANDIOIC ACID
**PEER REVIEWED**
PENTANEDIOIC ACID
**PEER REVIEWED**
1,5-PENTANEDIOIC ACID
**PEER REVIEWED**
1,3-PROPANEDICARBOXYLIC ACID
**PEER REVIEWED**
N-PYROTARTARIC ACID
**PEER REVIEWED**
Administrative Information:
Hazardous Substances Databank Number:
5542
Last Revision Date:
20030214
Update History:
Complete Update on 02/14/2003, 1 field added/edited/deleted.
Complete Update on 11/08/2002, 1 field added/edited/deleted.
Complete Update on 08/06/2002, 1 field added/edited/deleted.
Complete Update on 01/14/2002, 1 field added/edited/deleted.
Complete Update on 08/09/2001, 1 field added/edited/deleted.
Complete Update on 05/15/2001, 1 field added/edited/deleted.
Complete Update on 06/12/2000, 1 field added/edited/deleted.
Complete Update on 02/08/2000, 1 field added/edited/deleted.
Complete Update on 02/02/2000, 1 field added/edited/deleted.
Complete Update on 09/21/1999, 1 field added/edited/deleted.
Complete Update on 08/27/1999, 1 field added/edited/deleted.
Complete Update on 06/03/1998, 1 field added/edited/deleted.
Complete Update on 03/10/1998, 1 field added/edited/deleted.
Complete Update on 11/01/1997, 1 field added/edited/deleted.
Complete Update on 03/17/1997, 2 fields added/edited/deleted.
Complete Update on 01/30/1997, 1 field added/edited/deleted.
Complete Update on 05/14/1996, 1 field added/edited/deleted.
Complete Update on 01/29/1996, 1 field added/edited/deleted.
Complete Update on 01/05/1995, 1 field added/edited/deleted.
Complete Update on 04/04/1994, 1 field added/edited/deleted.
Field update on 01/08/1993, 1 field added/edited/deleted.
Complete Update on 10/10/1990, 1 field added/edited/deleted.
Complete Update on 04/16/1990, 1 field added/edited/deleted.
Field update on 03/06/1990, 1 field added/edited/deleted.
Complete Update on 01/16/1985